Company intelligence
Lindus
Next-generation drug development
Biotechnology Research
Boston, US
176 employees
4 public signals
About Lindus
Lindus Therapeutics is a next-generation drug development company. We advance portfolios of in-licensed assets, pairing our asset identification and selection capability with an integrated clinical trial delivery platform. Domain experts work hand in glove with proprietary AI systems that enable us and our partners to reach value inflection points faster and more efficiently than the industry standard. Lindus is backed by investors and advisors including Peter Thiel and Bob Langer.
Verified activity
Signals from Lindus
4 published signals
People
Lindus Therapeutics welcomed Dr. Gillian Cannon as a non-executive director.
Reported by Lindus
Strategy & Corporate Development
Lindus Therapeutics is in-licensing external assets and developing them through to value inflection points.
Reported by Lindus
Strategy & Corporate Development
Lindus leverages its trial delivery capability to progress its own assets
Reported by Michael Young
People
Lindus is hiring a Founding Head of Engineering to own engineering for Healf Zone, running a team of 5-7 developers.
Reported by George Morriss